Developing a robust process for protein production is critical in vaccine or biotherapeutic development. ExpreS²ion has developed several processes that have been successfully transferred to commercial manufacturers. By utilising process development, we can increase the protein yield considerably, thus reducing manufacturing costs.

We develop high-expressing monoclonal cell lines and robust processes and support transfer to cGMP facilities. The robust ExpreS² platform allows for various process modalities and intensification, enabling us to develop batch, fed-batch and perfusion processes using conventional bioreactors or single-use bioreactors. The characteristic robustness of the ExpreS² system provides extra flexibility when transferring processes to cGMP facilities.

To find out more about how we can support your process development, get in touch with us.